Yuki Okamoto

Yuki Okamoto

Auto-generated profile, based on publicly available information

Yuki Okamoto


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2026 in Organics
Verified
Journal Article
Open access
PDF file
FKFumihiro Kawagoe
Fumihiro Kawagoe
HTHiroya Tabuchi
Hiroya Tabuchi
TITaiyo Ideguchi
Taiyo Ideguchi
YOYuki Okamoto
Yuki Okamoto
SMSouma Murata
Souma Murata
AKAtsushi Kittaka
Atsushi Kittaka
We synthesized two vitamin D3 analogues, 3 and 4, which have a shortened or elongated fluoro-side-chain based on 24,24-difluoro-25-hydroxyvitamin D3 (5) using an efficient convergent approach and studied their preliminary biological activity. Both analogues exhibited greater resistance to CYP24A1-mediated metabolism than the natural 25-hydroxyvitamin D3 (6), although their stability was lower than that of 5. Analogue 3 showed an approximately 100-fold lower human vitamin D receptor (hVDR)-binding affinity compared with 5 and 6. Despite this marked reduction in VDR-binding affinity, it demonstrated an approximately 1.5-fold increase in VDR-ligand binding domain (LBD) transcriptional activation of the natural ligand 6. In contrast, analogue 4 displayed moderate VDR-binding affinity and VDR-LBD transactivation compared with 5 and 6. We found that compound 3 is a unique vitamin D analogue with a fluorinated and shortened side-chain, exhibiting low binding affinity for hVDR but potent transcriptional activity through VDR-LBD with its long half-life; thus, 3 may serve as a basic structural skeleton for advancing medicinal chemistry and drug discovery.